WallStreetZenWallStreetZen

NASDAQ: RAPT
Rapt Therapeutics Inc Stock

$8.98+0.05 (+0.56%)
Updated Mar 28, 2024
RAPT Price
$8.98
Fair Value Price
$1.06
Market Cap
$312.48M
52 Week Low
$6.86
52 Week High
$27.35
P/E
-2.94x
P/B
2.13x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$116.80M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.18
Operating Cash Flow
-$97M
Beta
1.27
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A

RAPT Overview

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. It also focuses on the development of hematopoietic progenitor kinase 1 inhibitor. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how RAPT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

RAPT ($8.98) is overvalued by 748.56% relative to our estimate of its Fair Value price of $1.06 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
RAPT ($8.98) is not significantly undervalued (748.56%) relative to our estimate of its Fair Value price of $1.06 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
RAPT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more RAPT due diligence checks available for Premium users.

Be the first to know about important RAPT news, forecast changes, insider trades & much more!

RAPT News

Valuation

RAPT fair value

Fair Value of RAPT stock based on Discounted Cash Flow (DCF)
Price
$8.98
Fair Value
$1.06
Overvalued by
748.56%
RAPT ($8.98) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
RAPT ($8.98) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
RAPT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

RAPT price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-2.94x
Industry
14.26x
Market
44.51x

RAPT price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
2.13x
Industry
6.21x
RAPT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

RAPT's financial health

Profit margin

Revenue
$0.0
Net Income
-$30.9M
Profit Margin
0%
RAPT's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$173.3M
Liabilities
$26.3M
Debt to equity
0.18
RAPT's short-term assets ($161.78M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RAPT's short-term assets ($161.78M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RAPT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
RAPT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$27.8M
Investing
$20.6M
Financing
$458.0k
RAPT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

RAPT vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
RAPT$312.48M+0.56%-2.94x2.13x
ERAS$312.08M0.00%-2.48x0.99x
XERS$310.40M+8.33%-4.91x-45.77x
PSTX$307.80M+3.57%-2.33x2.97x
INO$324.38M+6.52%-2.28x2.76x

Rapt Therapeutics Stock FAQ

What is Rapt Therapeutics's quote symbol?

(NASDAQ: RAPT) Rapt Therapeutics trades on the NASDAQ under the ticker symbol RAPT. Rapt Therapeutics stock quotes can also be displayed as NASDAQ: RAPT.

If you're new to stock investing, here's how to buy Rapt Therapeutics stock.

What is the 52 week high and low for Rapt Therapeutics (NASDAQ: RAPT)?

(NASDAQ: RAPT) Rapt Therapeutics's 52-week high was $27.35, and its 52-week low was $6.86. It is currently -67.17% from its 52-week high and 30.9% from its 52-week low.

How much is Rapt Therapeutics stock worth today?

(NASDAQ: RAPT) Rapt Therapeutics currently has 34,797,702 outstanding shares. With Rapt Therapeutics stock trading at $8.98 per share, the total value of Rapt Therapeutics stock (market capitalization) is $312.48M.

Rapt Therapeutics stock was originally listed at a price of $12.70 in Nov 1, 2019. If you had invested in Rapt Therapeutics stock at $12.70, your return over the last 4 years would have been -29.29%, for an annualized return of -8.3% (not including any dividends or dividend reinvestments).

How much is Rapt Therapeutics's stock price per share?

(NASDAQ: RAPT) Rapt Therapeutics stock price per share is $8.98 today (as of Mar 28, 2024).

What is Rapt Therapeutics's Market Cap?

(NASDAQ: RAPT) Rapt Therapeutics's market cap is $312.48M, as of Mar 29, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Rapt Therapeutics's market cap is calculated by multiplying RAPT's current stock price of $8.98 by RAPT's total outstanding shares of 34,797,702.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.